Purpose of this Study
If you choose to join this study, you will:
- Be randomized to Group 1 or Group 2
-- Group 1 will get the study drug (Sulindac)
-- Group 2 will get a placebo (harmless sugar pill)
Both groups will have:
- CT scans (body scan)
- Endoscopy's (a way to look at your digestive tract)
- Collection of cyst fluid from the pancreas
- Be randomized to Group 1 or Group 2
-- Group 1 will get the study drug (Sulindac)
-- Group 2 will get a placebo (harmless sugar pill)
Both groups will have:
- CT scans (body scan)
- Endoscopy's (a way to look at your digestive tract)
- Collection of cyst fluid from the pancreas
Who Can Participate?
Eligibility
- Men and women 21-85 years old
- Diagnosed with high-risk intraductal papillary mucinous neopolasm (IPMN)
- Diagnosed with high-risk intraductal papillary mucinous neopolasm (IPMN)
Age Range
18-85
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
We are doing this study to learn more about how the study drug, Sulindac, effects people with high risk intraductal papillary mucinous neoplasms (IPMN). The study drug (Sulindac) is a non-steroidal, anti-inflammatory medicine commonly called an NSAID.
Locations
Duke University Hospital
Duke Raleigh Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)
Principal Investigator
Peter
Allen
Protocol Number
PRO00103684
NCT ID
NCT04207944
Phase
II
Enrollment Status
OPEN TO ACCRUAL